Title : Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions.

Pub. Date : 2022 Feb

PMID : 34962076






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions. osimertinib epidermal growth factor receptor Homo sapiens